This study is looking into a new treatment called RO7837195 for people with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease. You might be able to join if you are 18 or older, have had UC for at least three months, and your current treatments haven't worked well enough. The study will compare RO7837195 to a placebo (an inactive substance) to see how well it helps people achieve clinical remission (a period where symptoms are reduced or absent) after 12 weeks. The study also aims to understand the safety of RO7837195 and how your body processes it. The current status of this study is unclear, and it plans to enroll 224 participants.

Study design

This interventional study will involve comparing RO7837195 to a placebo in 224 participants. It includes a 12-week induction phase where some participants receive the drug and others receive placebo, followed by an active treatment extension for all participants.

What's involved

You would participate in a screening period of up to 5 weeks, followed by a 12-week induction phase, and then a 40-week active treatment extension. There will also be a safety follow-up period after your last dose of the study treatment.

Compensation

Not stated in the trial record.

Follow-up

There will be a safety follow-up period after the last dose of study treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.